Overview

Metabolism Study to Investigate the Impact of a Sequential Oral Contraceptive

Status:
Completed
Trial end date:
2006-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to confirm the safety of SH T00658ID with regard to plasma lipids, hemostatic variables, and carbohydrate metabolism. In addition, the pharmacokinetic parameter following the long term administration of SH T00658ID will be assessed.
Phase:
Phase 2
Details
Lead Sponsor:
Bayer
Treatments:
Contraceptive Agents
Contraceptives, Oral
Contraceptives, Oral, Sequential
Ethinyl Estradiol-Norgestrel Combination